Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression

Osimertinib, a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is the standard treatment for patients with lung cancer harboring EGFR T790M; however, acquired resistance is inevitable due to genetic and epigenetic changes in cancer cells. In addition, a recent ran...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncol Lett
Main Authors: Nishii, Kazuya, Ohashi, Kadoaki, Watanabe, Hiromi, Makimoto, Go, Nakasuka, Takamasa, Higo, Hisao, Ninomiya, Kiichiro, Kato, Yuka, Kubo, Toshio, Rai, Kammei, Ichihara, Eiki, Hotta, Katsuyuki, Tabata, Masahiro, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2021
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8299008/
https://ncbi.nlm.nih.gov/pubmed/34386061
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2021.12900
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados